Dr. Lowe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1365 Clifton Rd NE
B-4003
Atlanta, GA 30322Phone+1 404-778-3303Fax+1 404-778-4255- Is this information wrong?
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2014 - 2016
- Emory University School of MedicineResidency, Surgery, 2007 - 2014
- Emory University School of MedicinePost-Doctoral Fellowship, Transplant Immunology, 2010 - 2012
- Georgetown University School of MedicineClass of 2007
- Georgetown UniversityMA, Bioethics, 2004 - 2005
- Saint Joseph's UniversityBS, Biology, Magna Cum Laude, 1998 - 2002
Certifications & Licensure
- GA State Medical License 2011 - 2026
- GA State Medical License 2010 - 2024
- NY State Medical License 2014 - 2017
- American Board of Surgery Surgery
- American Board of Surgery Complex General Surgical Oncology
Awards, Honors, & Recognition
- Alpha Omega Alpha 2006
- Phi Beta Kappa 2002
Clinical Trials
- VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma Start of enrollment: 2018 Dec 13
Roles: Principal Investigator
- Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer Start of enrollment: 2020 May 15
Roles: Principal Investigator, Contact
- Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma Start of enrollment: 2019 Dec 17
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 185 citationsNeoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright Jr, Kathleen J Yost
The New England Journal of Medicine. 2023-03-02 - 130 citationsNeoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N. Amaria, Alexander M. Menzies, Elizabeth M. Burton, Richard A. Scolyer, Michael T. Tetzlaff
The Lancet. Oncology. 2019-07-01 - 46 citationsBelatacept-Resistant Rejection Is Associated With CD28+ Memory CD8 T CellsDavid V. Mathews, W. C. Wakwe, Steven C. Kim, Michael C. Lowe, Cynthia A. Breeden
American Journal of Transplantation. 2017-09-01
Press Mentions
- Neoadjuvant Strategy Establishes Standard of Care for Resectable Stage III MelanomaJune 4th, 2024
Professional Memberships
- Member
- Member
- Member
- Member
- Member
Hospital Affiliations
- Emory University HospitalAtlanta, Georgia
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: